Monover (Ferric Derisomaltose)

Ferric derisomaltose delivers elemental iron bound to a stable carbohydrate complex. After intravenous infusion, the complex releases iron gradually, allowing uptake by reticuloendothelial cells and incorporation into transferrin for delivery to the bone marrow, where it supports hemoglobin synthesis.

The dose of Monover is individualized. The prescribing clinician determines the total iron requirement based on the patient’s weight, hemoglobin level, and iron deficit, and then calculates the appropriate volume for intravenous administration.

Safety data for ferric derisomaltose in pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Monover, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Monover (ferric derisomaltose) offers a stable carbohydrate‑iron complex that can be administered in a single high‑dose infusion, reducing the number of visits compared with some older IV iron formulations that require multiple smaller doses. Its safety profile is comparable, though individual patient factors guide product selection.

Monover must be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Do not use if the product appears discolored or contains particles.

Monover is given as an intravenous infusion by a qualified healthcare professional. The infusion rate and total volume are determined by the prescribed dose and the patient’s clinical condition, and the patient should be monitored for any adverse reactions during and after the infusion.

The most serious risks include severe hypersensitivity reactions such as anaphylaxis, marked hypotension, acute respiratory distress, and iron overload. Prompt recognition and immediate medical intervention are essential if any of these events occur.

Monover is contraindicated in patients with known hypersensitivity to ferric derisomaltose or any component of the formulation, and it should be used with caution in individuals with active infections, uncontrolled hypertension, or severe cardiac disease. The prescribing clinician must assess each patient’s suitability.